[go: up one dir, main page]

MX2016011025A - Composiciones de grapiprant y metodos para usar las mismas. - Google Patents

Composiciones de grapiprant y metodos para usar las mismas.

Info

Publication number
MX2016011025A
MX2016011025A MX2016011025A MX2016011025A MX2016011025A MX 2016011025 A MX2016011025 A MX 2016011025A MX 2016011025 A MX2016011025 A MX 2016011025A MX 2016011025 A MX2016011025 A MX 2016011025A MX 2016011025 A MX2016011025 A MX 2016011025A
Authority
MX
Mexico
Prior art keywords
grapiprant
compositions
methods
same
human animal
Prior art date
Application number
MX2016011025A
Other languages
English (en)
Other versions
MX376175B (es
Inventor
Devaraj Gopinath
RAUSCH-DERRA Lesley
NEWBOLD Tamara
Shiraishi Akemi
Original Assignee
Aratana Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54016294&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016011025(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aratana Therapeutics Inc filed Critical Aratana Therapeutics Inc
Publication of MX2016011025A publication Critical patent/MX2016011025A/es
Publication of MX376175B publication Critical patent/MX376175B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente descripción proporciona un método para el tratamiento del dolor o la inflamación en un animal no humano con necesidad del mismo. El método comprende la administración a un animal no humano de una composición farmacéutica que comprende una cantidad terapéuticamente eficaz de grapiprant. También se proporcionan en la presente composiciones farmacéuticas para el tratamiento del dolor o la inflamación en un animal no humano con necesidad del mismo. Las composiciones farmacéuticas comprenden una cantidad terapéuticamente eficaz de grapiprant y un excipiente, incluyendo saborizantes.
MX2016011025A 2014-03-06 2015-03-05 Composiciones de grapiprant y metodos para usar las mismas. MX376175B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461948957P 2014-03-06 2014-03-06
US201462089713P 2014-12-09 2014-12-09
PCT/US2015/019037 WO2015134792A1 (en) 2014-03-06 2015-03-05 Compositions of grapiprant and methods for using the same

Publications (2)

Publication Number Publication Date
MX2016011025A true MX2016011025A (es) 2016-11-29
MX376175B MX376175B (es) 2025-03-07

Family

ID=54016294

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2016011025A MX376175B (es) 2014-03-06 2015-03-05 Composiciones de grapiprant y metodos para usar las mismas.
MX2022014763A MX2022014763A (es) 2014-03-06 2016-08-24 Composiciones de grapiprant y metodos para usar las mismas.
MX2020001428A MX2020001428A (es) 2014-03-06 2016-08-24 Composiciones de grapiprant y metodos para usar las mismas.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2022014763A MX2022014763A (es) 2014-03-06 2016-08-24 Composiciones de grapiprant y metodos para usar las mismas.
MX2020001428A MX2020001428A (es) 2014-03-06 2016-08-24 Composiciones de grapiprant y metodos para usar las mismas.

Country Status (15)

Country Link
US (3) US11369621B2 (es)
EP (1) EP3113774B1 (es)
JP (1) JP6419857B2 (es)
KR (1) KR102270323B1 (es)
CN (2) CN112370450A (es)
AU (1) AU2015227059B2 (es)
CA (1) CA2941008C (es)
DK (1) DK3113774T3 (es)
ES (1) ES2907285T3 (es)
MX (3) MX376175B (es)
PL (1) PL3113774T3 (es)
PT (1) PT3113774T (es)
RU (1) RU2679631C2 (es)
TW (2) TWI708606B (es)
WO (1) WO2015134792A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12109218B2 (en) * 2014-12-09 2024-10-08 Aratana Therapeutics, Inc. Compositions of grapiprant and methods for using the same
CN112370450A (zh) * 2014-03-06 2021-02-19 阿莱塔纳治疗学股份有限公司 格拉匹纶组合物及其使用方法
EP3820480A4 (en) 2018-07-11 2022-03-09 Arrys Therapeutics, Inc. POLYMORPHIC COMPOUNDS AND USES THEREOF
US20210353648A1 (en) * 2018-09-27 2021-11-18 Arrys Therapeutics, Inc. Grapiprant unit dosage forms
WO2021205367A1 (en) * 2020-04-08 2021-10-14 Askat Inc. Use of ep4 receptor antagonists for the treatment of liver cancer, melanoma, lymphoma and leukemia

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ2479A1 (fr) 1997-05-05 2003-02-01 Pfizer Composés inhibiteurs sélectifs de cox-2 anti-inflammatoires et compositions pharmaceutiques les contenant.
AU6836200A (en) * 1999-08-10 2001-03-05 Glaxo Group Limited Use of ep4 receptor ligands in the treatment of, inter alia, neuropathic pain and colon cancer
HN2001000224A (es) 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
WO2003008637A2 (en) 2001-07-17 2003-01-30 Xanthus Life Sciences, Inc. Use of genotyping in the individualization of therapy
US20050059742A1 (en) * 2001-10-31 2005-03-17 Jabbour Henry Nicolas Antagonists of prostaglandin receptors ep2 and/or ep4 for the treatment of dysmenorrhea and menorphagia
CA2481535C (en) 2002-04-12 2010-08-17 Pfizer Inc. Use of ep4 receptor ligands in the treatment of il-6 involved diseases
BRPI0509993A (pt) 2004-04-20 2007-10-16 Pfizer Prod Inc combinações compreendendo ligandos de alfa-2-delta
MX2007011110A (es) * 2005-03-11 2008-02-21 Pfizer Formas de cristal de un derivado de imidazol.
US7968578B2 (en) * 2006-04-24 2011-06-28 Merck Frosst Canada Ltd. Indole amide derivatives as EP4 receptor antagonists
US20080242713A1 (en) * 2007-03-28 2008-10-02 Bayer Schering Pharma Aktiengesellschaft Novel 5-cyano-prostacyclin derivatives as agents for the treatment of autoimmune diseases
ES2600355T3 (es) 2010-02-22 2017-02-08 Raqualia Pharma Inc. Uso de un antagonista del receptor EP4 en el tratamiento de dermatitis de contacto alérgica y psoriasis
US20130225609A1 (en) * 2010-04-08 2013-08-29 Boehringer Ingelheim International Gmbh Combinations of medicaments, containing pde4-inhibitors and ep4-receptor-antagonists
AU2011316111B2 (en) 2010-10-12 2015-05-28 Merz Pharma Gmbh & Co. Kgaa Formulation suitable for stabilizing proteins, which is free of mammalian excipients
AU2012225459A1 (en) 2011-03-08 2013-10-10 Zalicus Pharmaceuticals Ltd. Solid dispersion formulations and methods of use thereof
KR20190015614A (ko) 2011-05-18 2019-02-13 라퀄리아 파마 인코포레이티드 4-｛[4-(｛[4-(2,2,2-트리플루오로에톡시)-1,2-벤즈이속사졸-3-일]옥시｝메틸)피페리딘-1-일]메틸｝-테트라히드로-2h-피란-4-카르복실산의 다형
ITBO20110461A1 (it) * 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
CN107496421A (zh) 2013-03-19 2017-12-22 株式会社ＡｓｋＡｔ Ep4受体拮抗剂在软骨疾病的治疗中的用途
WO2015134797A1 (en) 2014-03-06 2015-09-11 Aratana Therapeutics, Inc. Crystalline forms of grapiprant
CN112370450A (zh) * 2014-03-06 2021-02-19 阿莱塔纳治疗学股份有限公司 格拉匹纶组合物及其使用方法
US12109218B2 (en) * 2014-12-09 2024-10-08 Aratana Therapeutics, Inc. Compositions of grapiprant and methods for using the same

Also Published As

Publication number Publication date
US20150250773A1 (en) 2015-09-10
EP3113774A4 (en) 2017-10-25
CN112370450A (zh) 2021-02-19
US20250025481A1 (en) 2025-01-23
DK3113774T3 (da) 2022-03-07
PL3113774T3 (pl) 2022-06-13
TWI664969B (zh) 2019-07-11
NZ761827A (en) 2021-03-26
MX376175B (es) 2025-03-07
JP6419857B2 (ja) 2018-11-07
EP3113774B1 (en) 2022-01-26
PT3113774T (pt) 2022-02-28
EP3113774A1 (en) 2017-01-11
US11369621B2 (en) 2022-06-28
TW201815393A (zh) 2018-05-01
NZ724007A (en) 2021-02-26
ES2907285T3 (es) 2022-04-22
AU2015227059B2 (en) 2018-11-15
US20160317559A1 (en) 2016-11-03
RU2019102384A3 (es) 2022-03-31
AU2015227059A1 (en) 2016-09-22
JP2017507190A (ja) 2017-03-16
KR20160129887A (ko) 2016-11-09
WO2015134792A1 (en) 2015-09-11
TWI708606B (zh) 2020-11-01
RU2679631C2 (ru) 2019-02-12
CA2941008C (en) 2022-07-26
RU2016137926A (ru) 2018-04-09
TW201603812A (zh) 2016-02-01
US12478633B2 (en) 2025-11-25
CA2941008A1 (en) 2015-09-11
MX2022014763A (es) 2023-01-11
RU2019102384A (ru) 2019-03-04
KR102270323B1 (ko) 2021-06-29
CN105939713A (zh) 2016-09-14
MX2020001428A (es) 2020-03-20

Similar Documents

Publication Publication Date Title
CO2019006291A2 (es) Composiciones de aminoácidos y métodos de tratamiento de enfermedades hepáticas
CR20160200A (es) Combinaciones de inhibidores de histona desacetilasa y fármacos inmunomoduladores
JOP20200001A1 (ar) كاربوكسأميدات بوصفها معدلات لقنوات الصوديوم
MX366317B (es) Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias.
CL2016002516A1 (es) “compuestos derivados de espirociclo sustituidos, inhibidores atx; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer, inflamaciones, dolor neuropático, enfermedades fibróticas, trombosis, entre otros”. pct
NI201600071A (es) Compuestos de inhibidor de autotaxina
EA201591751A1 (ru) Трипептидные эпоксикетонные ингибиторы протеазы
MX2016011810A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
MX2015009045A (es) Composiciones y metodos para tratar el dolor severo.
CR20160308A (es) Combinaciones de inhibidores de histona deacetilasa y farmacos inmunomoduladores
MX2015014656A (es) Formulaciones de liberacion prolongada de colchicina y metodos de uso de las mismas.
MX2017006113A (es) Nuevos profarmacos polimericos de la hormona del crecimiento humana (hgh).
CL2018000811A1 (es) Formulaciones de aminoácidos de liberación modificada administradas por vía oral.
UY35455A (es) Inhibidores tripeptidicos de la epoxicetona proteasa
CR20150637A (es) Tratamiento de enfermedades miopaticas y neurodegenerativas por agregación de proteina mediante administración parenteral
CL2019002218A1 (es) Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
CO7141430A2 (es) Formulaciones vesiculares para uso en el tratamiento del dolor o movilidad reducida de una articulación
BR112018069682A2 (pt) métodos de tratamento para doenças colestáticas e fibróticas
MX2018012230A (es) Métodos para tratar enfermedades oculares.
MX2016011025A (es) Composiciones de grapiprant y metodos para usar las mismas.
MX2018005628A (es) Tratamientos de grasa acumulada con acido desoxicolico y sales del mismo.
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
PH12016500910A1 (en) Long-acting ketoprofen compositions
ECSP16086232A (es) (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina

Legal Events

Date Code Title Description
FG Grant or registration